Cosmo Pharmaceuticals NV (LTS:0RGI) Short Interest

View and export this data going back to 2014. Start your Free Trial

What is Cosmo Pharmaceuticals NV Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Cosmo Pharmaceuticals NV's Short Interest

For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cosmo Pharmaceuticals NV's Short Interest Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's Short Interest distribution charts can be found below:

* The bar in red indicates where Cosmo Pharmaceuticals NV's Short Interest falls into.

Cosmo Pharmaceuticals NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (LTS:0RGI) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

COPNz:UK C43:Germany COPN:Switzerland

Address

Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2

Website

https://www.cosmopharma.com

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV Headlines

No Headlines